Nexalin Technology (NXL) Stock Price, News & Analysis

Company Overview

Nexalin Technology, Inc. is a medical technology company focused on developing noninvasive neurostimulation devices designed to support brain health. Its technology uses cranial electrotherapy stimulation to deliver low-level electrical signals through electrodes placed on the head, with the aim of influencing brain activity without surgery or implanted hardware.

The company’s product portfolio includes the Nexalin Gen-2 and Gen-3 devices, which are designed for use in clinical and other supervised settings. Nexalin has pursued applications for conditions and symptoms including insomnia, anxiety, depression and post-traumatic stress disorder, although the regulatory status and approved uses of its products may vary by jurisdiction.

Nexalin Technology has worked to commercialize its devices in the United States and international markets through regulatory initiatives, clinical research and distribution relationships. The company’s operations are centered on advancing its neurostimulation platform and expanding access to its products for healthcare providers and patients.

Key Stats

• Today's Range: $5.15 to $5.95
• 50-Day Range: $4.27 to $13.26
• 52-Week Range: $4.00 to $60.00
• Volume: 1.35 million shs
• Average Volume: 3.13 million shs
• Market Capitalization: $4.18 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Reduce

Nexalin Technology Stock Analysis - MarketRank™

Nexalin Technology scored higher than 35% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.2 / 5
• Analyst Rating: Reduce

Consensus Rating

Nexalin Technology has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and 1 sell rating.

Amount of Analyst Coverage

Nexalin Technology has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Nexalin Technology are expected to grow in the coming year, from ($11.40) to ($9.30) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Nexalin Technology is -0.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Nexalin Technology is -0.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Nexalin Technology has a P/B Ratio of 0.95. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.05% of the float of Nexalin Technology has been sold short.

Short Interest Ratio / Days to Cover

Nexalin Technology has a short interest ratio ("days to cover") of 0.66, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Nexalin Technology has recently decreased by 8.56%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Nexalin Technology does not currently pay a dividend.

Dividend Growth

Nexalin Technology does not have a long track record of dividend growth.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 0.44

News Sentiment

Nexalin Technology has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 22 news articles for Nexalin Technology this week, compared to 3 articles on an average week.

Search Interest

6 people have searched for NXL on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.

MarketBeat Follows

1 people have added Nexalin Technology to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.6 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Nexalin Technology insiders have not sold or bought any company stock.

Percentage Held by Insiders

16.94% of the stock of Nexalin Technology is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

0.65% of the stock of Nexalin Technology is held by institutions.

Company Calendar

• Last Earnings: 8/12/2026
• Today: 10/03/2026
• Next Earnings (Estimated): 12/02/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:NXL
• CIK: 1527352
• Web: www.nexalin.com
• Phone: 832-260-0222
• Fax: N/A
• Employees: 8
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($14.41)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$8.22 million
• Net Margins: -4,141.94%
• Pretax Margin: -4,142.40%
• Return on Equity: -278.24%
• Return on Assets: -218.42%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.25
• Quick Ratio: 1.10

Sales & Book Value

• Annual Sales: $300 thousand
• Price / Sales: 13.94
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.03 per share
• Price / Book: 0.95

Miscellaneous

• Outstanding Shares: 730,000
• Free Float: 610,000
• Market Cap: $4.18 million
• Optionable: Not Optionable
• Beta: 4.08